TAM
AARD

TFG Asset Management’s Aardvark Therapeutics AARD Stock Holding History

TFG Asset Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-316,621
Closed -$1.19M – 45
2026
Q1 		$1.19M Buy
+316,621
New +$3.28M 0.23% 32

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

TFG Asset Management's AARD Position: Q2 2026 in Review

TFG Asset Management sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 316,621 shares — an estimated $1.19M sold.

TFG Asset Management first reported a position in AARD in Q1 2026 and held it in 1 quarter. The position peaked at $1.19M in Q1 2026. 72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • TFG Asset Management reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TFG Asset Management sold 316,621 Aardvark Therapeutics shares in Q2 2026, an estimated $1.19M.
  • TFG Asset Management first reported a position in Aardvark Therapeutics in Q1 2026 and held it in 1 quarter.
  • TFG Asset Management's Aardvark Therapeutics position peaked at $1.19M in Q1 2026.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.